论文信息 - Lack of a Clinically Relevant Effect of an Antacid on the Pharmacokinetics of Lersivirine

Lack of a Clinically Relevant Effect of an Antacid on the Pharmacokinetics of Lersivirine

ABSTRACT Lersivirine (UK-453,061) is a next-generation nonnucleoside reverse transcriptase inhibitor that displays potent antiviral activity. Lersivirine solubility is pH dependent; therefore, the effect of coadministration of antacid on the pharmacokinetics of lersivirine in healthy subjects was investigated. The ratio of adjusted geometric means (750 mg lersivirine plus 20 ml Maalox Max/750 mg lersivirine alone) for the area under the curve from time zero extrapolated to infinite time (AUCinf) was 101.86%, showing that coadministration of an antacid had no effect on lersivirine exposure. Coadministration appeared to be safe and relatively well tolerated.

R. Labadie | M. Vourvahis | H. Mayer | S. Banerjee | D. Gore

[1] S. Staszewski,et al. Activity, pharmacokinetics and safety of lersivirine (UK-453,061), a next-generation nonnucleoside reverse transcriptase inhibitor, during 7-day monotherapy in HIV-1-infected patients , 2009, AIDS.

[2] M. Stevens,et al. The pharmacokinetic (PK) interaction between omeprazole and TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) , 2008 .

[3] J. van Lunzen,et al. Concomitant use of gastric acid‐reducing agents is frequent among HIV‐1‐infected patients receiving protease inhibitor‐based highly active antiretroviral therapy * , 2007, HIV medicine.